UNITED
STATES
 SECURITIES
AND EXCHANGE COMMISSION
 Washington,
D.C. 20549
 
 FORM
10-Q
  (Mark
One)
 x QUARTERLY
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
 
 For the
quarterly period ended March 31, 2009
 
 o TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
 
 000-31469
 (Commission
file number)
 
 Medical International
Technology, Inc.
 (Exact
name of small business issuer as specified in its charter)
  Colorado
                
                84-1509950(State
      or other jurisdiction
                  of
      incorporation or organization)
                
                (IRS
      Employer Identification No.)
  1872
Beaulac
 Ville
Saint-Laurent
 Montrйal,Quйbec,CanadaH4R 2E7
 (Address
of principal executive offices)
 
 (514)
339-9355
 (Issuer's
telephone number)
 
 
 (Former
name, former address and former fiscal year, if changed since last
report)
 
 Check
whether the issuer (1) filed all reports required to be filed by Section 13 or
15(d) of the Exchange Act during the past 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days. Yes x No o
  Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). Yes o        No
o
  Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company.  See the definitions of “large accelerated filer,”
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act.
  Large
accelerated filer   o                                                                                               Accelerated
filer o
  Non-accelerated
filer     o                                                                                               Smaller
reporting company x
 (Do
not check is a smaller reporting company)
  Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes o No x
 
 The
number of shares outstanding of each of the issuer's classes of common equity as
of March 31, 2009: 51,058,663 shares of common stock
 
 Transitional Small Business Disclosure Format (check
one): Yes o
No x
   
    PART
      I.    FINANCIAL INFORMATIONItem
      1.      Consolidated Financial
      Statements
              3Consolidated
      Balance Sheet
              3Consolidated
      Statements of Operations,
              5Consolidated
      Statements of Cash Flows
              6Consolidated
      Statements of Comprehensive Loss
              7Consolidated
      Statement of Stockholders’ (Deficit)
              8Notes
      to Unaudited Consolidated Financial Statements
              8Item
      2.       Management's Discussion and
      Analysis of Financial Condition and Plan of
    Operations
              12Item
      3.       Quantitative and Qualitative
      Disclosures About Market Risk
              14Item
      4.       Controls and
      Procedures
              14Part
      II. OTHER INFORMATIONItem
      1        Legal
      Proceedings
              15Item
      1A.    Risk Factors
              15Item
      2.       Unregistered Sales of Equity
      Securities and Use of Proceeds
              15Item
      3.       Defaults upon Senior
      Securities
              15Item
      4.       Submission of Matters to a
      Vote of Security Holders
              15Item
      5.       Other
    Information
              16Item
      6.       Exhibits and Reports on Form
      8-K
              15SIGNATURES
              16
   -2-
   Item
1. Financial Information
   Medical
      International Technology, Inc.
              Quarterly Financial
      Report
  CONSOLIDATED BALANCE SHEETMarch
      31, 2008
                      
                      
                      September
      30, 2008(Unaudited)
                      
                      
                      (Audited)AssetsCurrent
      AssetsCash and cash
      equivalents
                      
                      $
                      48,237
                      
                      
                      $
                      94,834Accounts
      receivable
                      
                      
                      10,222
                      
                      
                      
                      ---Inventories
                      
                      
                      169,469
                      
                      
                      
                      169,459Prepaid
      expenses
                      
                      
                      6,656
                      
                      
                      
                      3,565Total
      Current Assets
                      
                      
                      234
      584
                      
                      
                      
                      267,858Property
      and EquipmentTooling and
      machinery
                      
                      
                      229,823
                      
                      
                      
                      229,823Furniture and
      office equipment
                      
                      
                      133,014
                      
                      
                      
                      133,014Leasehold
      improvements
                      
                      
                      22,163
                      
                      
                      
                      22,163385,000
                      
                      
                      
                      385,000Less accumulated
      depreciation
                      
                      
                      (326,183
                      )
                      
                      
                      (299,500
                      )58
      817
                      
                      
                      
                      85,500Other
      AssetsPatents (net
      accumulated amortization of $1,631 and $1,398)
                      
                      
                      399
                      
                      
                      
                      632Total
      Assets
                      
                      $
                      293,800
                      
                      
                      $
                      353,990
   -3-
   Medical
      International Technology, Inc.
              Quarterly Financial
      Report
  CONSOLIDATED BALANCE SHEETMarch
      31,
                    2009
                  
                  
                  September
      30,
                    2008(Unaudited)
                  
                  
                  (Audited)Liabilities
      and Stockholders' Equity (Deficit)Current
      LiabilitiesDeferred
      income
                  
                  $
                  1,374,036
                  
                  
                  $
                  1,353,782Accounts payable
      and accrued expenses
                  
                  
                  302,033
                  
                  
                  
                  90,245Amounts due to
      related parties
                  
                  
                  2,212,833
                  
                  
                  
                  1,524,321Current portion of
      long-term debts
                  
                  
                  7,740
                  
                  
                  
                  8,2373,896,642
                  
                  
                  
                  2,976,585Long-Term
      Debts
                  
                  
                  447
                  
                  
                  
                  6,860Total
      Liabilities
                  
                  
                  3,897,089
                  
                  
                  
                  2,983,445Stockholders'
      Equity (Deficit)Preferred stock,
      $.0001 par value; 3,000,000 shares authorized;None issued and
      outstanding as of December 31, 2007Common stock,
      $.0001 par value; 100,000,000 shares authorized;51,058,663
      and 27,058,663 shares issued andOutstanding,
      respectively
                  
                  
                  5,106
                  
                  
                  
                  2,706Additional paid-in
      capital
                  
                  
                  6,825,939
                  
                  
                  
                  6,804,339Deficit
                  
                  
                  (10,427,161
                  )
                  
                  
                  (9,333,413
                  )Othercomprehensive income
      (loss)
                  
                  
                  (7,173
                  )
                  
                  
                  (103,087)Total Stockholders' Equity
      (Deficit)
                  
                  
                  (3,603,289
                  )
                  
                  
                  (2,629,455
                  )Total Liabilities
      and Stockholders' Equity (Deficit)
                  
                  $
                  293,800
                  
                  
                  $
                  353,990
   -4-
   Medical
      International Technology, Inc.
              Quarterly Financial
      Report
   CONSOLIDATED STATEMENTS OF
OPERATIONS
   Three-Months
      Period
                              EndedMarch
      31,
                            
                            
                            Six-Months
      Period
                              EndedMarch
      31,2009
                              (Unaudited)
                            
                            
                            2008
                              (Unaudited)
                            
                            
                            2009
                              (Unaudited)
                            
                            
                            2008
                              (Unaudited)Sales
                            
                            $
                            88,002
                            
                            
                            $
                            46,915
                            
                            
                            $
                            158,917
                            
                            
                            $
                            165,507Cost
      of sales
                            
                            
                            ( 34,151
                            )
                            
                            
                            ( 47,932
                            )
                            
                            
                            (85,761
                            )
                            
                            
                            (99,331
                            )Gross
      profit (loss)
                            
                            
                            53,851
                            
                            
                            
                            (1,017
                            )
                            
                            
                            73,156
                            
                            
                            
                            66,176Research
      and development costs
                            
                            
                            (450,000
                            )
                            
                            
                            125,989
                            
                            
                            
                            (900,000
                            )
                            
                            
                            181,053Selling,
      general, and administrative expenses
                            
                            
                            ( 115,861
                            )
                            
                            
                            164,045
                            
                            
                            
                            (266,239
                            )
                            
                            
                            336,104(565,861
                            )
                            
                            
                            290,034
                            
                            
                            
                            (1,166,239
                            )
                            
                            
                            517,157Loss
      from operations
                            
                            
                            (512,010
                            )
                            
                            
                            (291,051
                            )
                            
                            
                            (1,093,083
                            )
                            
                            
                            (450,981
                            )Other
      Income (Expense)Interest
      income/loss
                            
                            
                            (798
                            )
                            
                            
                            11,499
                            
                            
                            
                            514
                            
                            
                            
                            12,267Interest
      expense
                            
                            
                            (538
                            )
                            
                            
                            (2,005
                            )
                            
                            
                            (1,179
                            )
                            
                            
                            (16,117
                            )(1,336
                            )
                            
                            
                            9,494
                            
                            
                            
                            (665
                            )
                            
                            
                            (3,850
                            )Net
      Loss
                            
                            $
                            (513,346
                            )
                            
                            $
                            (281,557
                            )
                            
                            $
                            (1,093,748
                            )
                            
                            $
                            (454,831
                            )Basic
      (loss) per share
                            
                            $
                            (0.01
                            )
                            
                            $
                            (0.01
                            )
                            
                            $
                            (0.02
                            )
                            
                            $
                            (0.02
                            )Basic
      weighted average shares outstanding
                            
                            
                            51,058,663
                            
                            
                            
                            27,058,663
                            
                            
                            
                            45,915,806
                            
                            
                            
                            27,058,663
 
  -5-
  Medical
      International Technology, Inc.
              Quarterly Financial
      Report
  CONSOLIDATED STATEMENTS OF CASH
      FLOWSSix-Month
      Period EndedMarch
      31,2009
                              
                              
                              2008Cash
      Flows from Operating Activities
                              
                              (Unaudited)
                              
                              
                              (Unaudited)Net
      Loss
                              
                              $
                              (1,093,748
                              )
                              
                              $
                              (454,831
                              )Adjustments to
      reconcile net loss to net cashUsed in
      operating activities:Depreciation
      and amortization expense
                              
                              
                              26,915
                              
                              
                              
                              27,647Common stock issued
      for consulting and legal services
                              
                              
                              2,400
                              
                              
                              
                              -Related party
      payables settle by common stock
                              
                              
                              21,600761(Increase)
      decrease in Assets(Increase)
      decrease in accounts receivable
                              
                              
                              (10,222
                              )
                              
                              
                              761(Increase)
      decrease in inventories
                              
                              
                              (10
                              )
                              
                              
                              10,198(Increase)
      decrease in research tax credit receivable
                              
                              
                              -
                              
                              
                              
                              13,889(Increase)
      decrease in prepaid expenses
                              
                              
                              (3,091)
                              
                              
                              
                              2,764Increase
      (decrease) in LiabilitiesIncrease
      (decrease) in deferred income
                              
                              
                              20,255
                              
                              
                              
                              1,292,476Increase
      (decrease) in accounts payable and accrued expenses
                              
                              
                              211,788
                              
                              
                              
                              (158,165
                              )Net
      Cash Used in Operating Activities
                              
                              
                              (824,113
                              )
                              
                              
                              734,739Cash
      Flows from Investing ActivitiesEquipment
      acquisition
                              
                              
                              -
                              
                              
                              
                              (3,423
                              )Net
      cash used in investing activities
                              
                              
                              -
                              
                              
                              
                              (3,423
                              )Cash
      Flows from Financing ActivitiesGross proceeds from
      private offering
                              
                              
                              -
                              
                              
                              
                              -Borrowings
      (reductions) in amounts due to related parties
                              
                              
                              688,512
                              
                              
                              
                              (49,696
                              )Principal reduction
      on small business loan
                              
                              
                              (6,910
                              )
                              
                              
                              (267,822
                              )Net Cash Provided
      by Financing Activities
                              
                              
                              681,602
                              
                              
                              
                              (317,518
                              )Effect
      of exchange rates on cash
                              
                              
                              95,914
                              
                              
                              
                              (152,379
                              )Net
      Increase (decrease) in Cash and Cash Equivalents
                              
                              
                              (46,597
                              )
                              
                              
                              261,419Beginning
      Balance - Cash and Cash Equivalents
                              
                              
                              94,834
                              
                              
                              
                              187,536Ending
      Balance - Cash and Cash Equivalents
                              
                              $
                              48,237
                              
                              
                              $
                              448,955Supplemental
      Information:Cash Paid
      For:Interest
      Expenses
                              
                              $
                              641
                              
                              
                              
                              16,117Income
      Taxes
                              
                              $
                              -
                              
                              
                              $
                              -$
                              
                              
                              
                              $
                              -
   -6-
  Medical
      International Technology, Inc.
                Quarterly Financial
      Report
 CONSOLIDATED STATEMENTS OF COMPREHENSIVE
      LOSSSix
      months ending
                        March
      31,
                        2009
                      
                      
                      Six
                        months
      ending
                        March
      31,
                        2008Net
      loss
                      
                      $
                      (1,093,748
                      )
                      
                      $
                      (454,831
                      )Other
      comprehensive income (loss)Foreign currency
      translation adjustment
                      
                      
                      95,914
                      
                      
                      
                      (152,379)Net comprehensive income (loss)
                      
                      $
                      (997,834
                      )
                      
                      $
                      (607,210
                      )
    -7-
    Medical
      International Technology, Inc.
              Quarterly Financial
      Report
  Notes
to Financial Statements
 
 (Unaudited)
  Note
1 – Basis of Presentation
  Interim
Financial Statements
 The
accompanying unaudited condensed consolidated financial statements of Medical
International Technology, Inc. and its subsidiary (collectively referred to as
the “Company”) have been prepared in accordance with accounting principles
generally accepted in the United States of America, pursuant to the rules and
regulations of the Securities and Exchange Commission.  All
significant intercompany balances and transactions have been
eliminated.  These financial statements do not include all information
and notes required by accounting principles generally accepted in the United
States of America for complete financial statements.  It is
recommended that these interim unaudited condensed consolidated financial
statements be read in conjunction with the consolidated financial statements and
notes thereto included in the Company's Annual Report on Form 10-K for the
fiscal year ended September 30, 2008.
  In the
opinion of management, all adjustments (consisting only of normal recurring
accruals) considered necessary for a fair presentation have been
included.  Operating results for the six month period ended March 31,
2009 are not necessarily indicative of the results which may be expected for any
other interim periods or for the year ending September 30, 2009. The preparation
of financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from these estimates.
  Note
2 – Unearned income
 
 On
November 1, 2007, the Company received a Non-Refundable deposit of $1,300,000
from a distribution company for the worldwide rights to market and sells all
Medical International Technology Inc.’s present and future Needle-Free
Jet-Injectors for the human and animal markets. This deposit was part of an
agreement under negotiation, which the Company finalized in January
2009.  The agreement term is 10 years, with certain conditions that
must be meet by January 2010, including the ability of the distribution company
to fund an additional $1,000,000 by January 2010.  The Company has no
obligation to refund any of the initial deposit. The Company has recorded the
deposit as unearned income, and the deferred income will be earned as
income monthly over the next 10 years.  During the qurarter ended
March 31, 2009, the Company recorded $32,500 in earned revenue under this
agreement.
 
 Note
3 – Inventories
  Inventories
at December 31, 2008 and September 30, 2008 consist of the
following:
  March
      31,
                      2008
                    
                    
                    September
      30,
                      2008Raw
      materials
                    
                    $
                    136,792
                    
                    
                    $
                    139,604Work
      in process
                    
                    
                    28
      208
                    
                    
                    
                    23,863Finished
      goods
                    
                    
                    4,469
                    
                    
                    
                    5,992Total
                    
                    $
                    169,469
                    
                    
                    $
                    169,459
  -8-
   Medical
      International Technology, Inc.
              Quarterly Financial
      Report
  Notes
to Financial Statements
 
 (Unaudited)
  Note
4 – Research Credit Receivable
  Research
and development costs are charged to operations when incurred. For its research
efforts in Canada, the Company receives a cash payment from the Canadian
Government based upon the amount actually incurred. The Company nets the credit
against related costs charged to operations. Research and development expenses
are as follows:
  March
      31,
                      2008
                    
                    
                    September
      30,
                      2008R&D
      Costs
                    
                    $
                    900,000
                    
                    
                    $
                    1,802,857Less
      Credit
                    
                    
                    -
                    
                    
                    
                    (3,158
                    )$
                    900,000
                    
                    
                    $
                    1,802,085
  Note
5 – Property and Equipment
  The cost
of property and equipment is depreciated over the estimated useful lives of the
related assets, which range from 5 to 7 years. Depreciation is computed on the
straight-line method for financial reporting purposes and on the declining
balance method for income tax reporting purposes. Depreciation expense for the
six-months ended March 31, 2009 and 2008 was $26,682, and $27,647
respectively.
  Note
6 – Intangible Assets
  As of
March 31, 2009 the Company has net intangible assets totaling $ 399.
Amortization expenses for the three-months ended March 31, 2009 and 2008 were
$233, and $233, respectively.  Intangible assets consist of the
following:
  Gross
                  Intangible
                  Assets
                
                
                Accumulated
      Amortization
                
                
                Net
                  Intangible
                  Assets
                
                Weighted
                  Average
                  Life
                  (Years)Patents
                
                $
                2,030
                
                
                $
                1,631
                
                
                $
                399
                
                8.5
      through 16
  Note
7 – Related Party Transactions
 
 Related
party balances consist of the following at March 31, 2009 and September 30,
2008:
  March
      31,
                        2009
                      
                      
                      September
      30,
                        2008Payable
      to Idee International R&D, Inc.
                      
                      $
                      2,212,833
                      
                      
                      $
                      1,480,378Payable
      to 2849-674 Canada, Inc.
                      
                      
                      -
                      
                      
                      
                      34,637Payable
      to 9117-2221 Quebec Inc.
                      
                      
                      -
                      
                      
                      
                      9,306$
                      2,212,833
                      
                      
                      $
                      1,524,321
  The
Company, from time to time, has borrowed from shareholders and corporations
owned by shareholders. These loans are non-interest bearing and due upon demand.
In addition, the Company has advanced funds to other corporations owned by
shareholders. These loans are also non-interest bearing and due upon
demand.
 
 During
fiscal 2008 and effective October 1, 2007, the Company entered into a Research
and Development Contract with Idee International R&D, Inc.(“Idee”), an
entity owned individually by the Company’s CEO and President.  Under
the terms of the agreement, Idee will perform specific research and development
on needle-free technologies, as defined in the agreement, from October 1, 2007
to September 30, 2009, and the Company will pay Idee $150,000 per
month.  The monthly charge is recorded as research and development
costs on the accompanying consolidated income statement.  The Company
has accrued a liability to Idee of $ 2,212,833under this contract.
  -9-
   Medical
      International Technology, Inc.
              Quarterly Financial
      Report
  Notes
to Financial Statements
 
 (Unaudited)
 
 Note 8 –
Stock Activity
 
 Common
Stock
  From time
to time, the Company will issue common stock for services rendered, debt
reductions or as part of private placement offerings.  For the quarter
ended December 31, 2008, the Company issued 20,000,000 shares of common stock to
a related party for payment of outstanding payables of $20,000.  In
addition, the Company issued 2,000,000 shares of common stock to the Company’s
Chief Executive Officer and 2,000,000 shares to the Company’s Chief Financial
Officer for services rendered to the Company.  The value of those
services was $4,000.
 
 The
Company did not issue any common shares during the quarter ended March 31,
2009.
  Preferred
Stock
  As of
March 31, 2009, there was no preferred stock outstanding. Dividend features and
voting rights are at the discretion of the Board of Directors without the
requirement of shareholder approval.
  Outstanding
Options
  As of
March 31, 2009, there were no outstanding stock options.
  Outstanding
Warrants
  As of
March 31, 2009, there were no outstanding warrants.
  Note
9 – Notes Payable
 
 Long-term
debt consists of the following at March 31, 2009 and September 30,
2008:
  March
      31,
                      2008
                    
                    
                    September
      30,
                      2008Note
      payable to a bank, bearing interest at prime plus
    2.5%secured by equipment, due July 21, 2010.
                    
                    $
                    8,187
                    
                    
                    $
                    15,097Current
      portion of long-term debt
                    
                    
                    (7,740)
                    
                    
                    
                    (8,237
                    )Long-term
      debt
                    
                    $
                    447
                    
                    
                    $
                    6,860Scheduled
      maturities of long-term debt are as follows:March
      31, 2010
                    
                    
                    7,740July
      31, 2010
                    
                    
                    447
  Note
10 – Subsequent Events
 
 In April
2009, the company issued 2,000,000 common shares for$ 200,000 as part of the
private placement agreement. Proceeds
of the private placement will be used to fund operation
 
  -10-
  Medical
      International Technology, Inc.
              Quarterly Financial
      Report
  Notes
to Financial Statements
 
 (Unaudited)
  
 Note
11 – Contingencies
  Legal
Proceedings
  From time
to time, the Company is named in legal actions in the normal course of business.
In the opinion of management, the outcome of these matters, if any, will not
have a material impact on the financial condition or results of operations of
the Company.
   -11-
  Medical
International Technology, Inc.
   Item
2.   Management's Discussion and Analysis of Financial Condition
and Plan of Operations
 
 All
statements that are included in this Quarterly Report, other than statements of
historical fact, are forward looking statements.  Although management
believes that the expectations reflected in these forward looking statements are
reasonable, it can give no assurance that such expectations will prove to have
been correct.
  Financial
Summary
  Results of Operations for
the Six-Months ended March 31, 2009 and 2008
  For the
six-month period ended March 31, 2009, the Company experienced a net loss from
operations of  $1,093,083 which was primarily due to research and
development costs of  $900,000 and selling, general and administrative
expenses of  $266,239. Gross profits for the period were
$73,156.
 
 For the
six-month period ended March 31, 2008, the Company’s net loss from operations
was $450,981, which was primarily due to research and development costs
of  $181,053 and selling, general and administrative expenses of
$336,101. Gross profits for this period were $66,176.
 
 For the
six-months ended March 31, 2009, the Company experienced a decrease in sales
compared to sales for the same period last year. Sales for the six-month period
ending March 31, 2009 were $158,917 compared to sales of $165,507 for the same
period last year. Gross profits for the period ending March 31, 2009 represented
46% of sales, where gross profits for the same period last year represented 40%
of sales.
  Liquidity and Capital
Resources
 
 For the
six-month period ending March 31, 2009, the Company’s cash position decreased
$46,597. Net cash used in operating activities was $824,113; financing
activities provided $681,602; and the effect of exchange rates on cash provided
$95,914
  For the
six-month period ending March 31, 2008, the Company’s cash position increased
$261,419. Net cash used in operating activities was $734,739; financing
activities provided $317,518; and the effect of exchange rates on cash provided
$152,379.
 
 Management
Plan of Operations
 
 Medical
International Technology, Inc. (“MIT”) is engaged in the business of research,
development, marketing and sales of needle-free jet injector technology and
products for humans and animals, for single and mass injections.
 
 We
continue to market our product in all available markets, seek regulatory
approvals to expand those market opportunities and improve our products for
application to new markets.
 
 Medical
International Technology, Inc. will continue to seek additional funding to
expand operations and develop sales revenue to a volume sufficient to sustain
operations.
   -12-
  Medical
International Technology, Inc.
  
 Product
Development
 
 Medical
International Technologies is still working towards getting FDA approval for its
needle-free injector, few more test are required and are being planned – the
MED-JET, designed specifically for human mass inoculations. The MED-JET is
capable of delivering many types of medications such as vaccines, insulin and
other types of injectables. Its low-pressure technology offers an advantage to
alternative high pressure systems that can cause blowbacks and expose medical
workers and patients alike to microscopic traces of blood.
 
 According
to the International Sharps Injury Prevention Society (http://www.isips.org), it
has been estimated that one out of every seven workers is accidentally stuck by
a contaminated sharp point each and every year. The Center for Disease Control
(CDC: http://www.cdc.gov/niosh/2000-108.html#5) estimates that there are 600,000
to 800,000 needle stick injuries per year in the U.S. alone, and many are not
reported. More than 20 types of infectious agents have been transmitted through
needlesticks, including hepatitis B and C, tuberculosis, syphilis, malaria,
herpes, diphtheria, gonorrhea, typhus and Rocky Mountain spotted fever. The
MED-JET will eliminate this risk to our health care professionals and create a
safer workplace. Other advantages include its light weight (0.5 kg) and an
excellent medication absorption rate. Additionally, the system has the ability
to increase or decrease the volume and pressure of injection. This technology is
unique to MIT’s MED-JET MBX Injector. The system is designed to inject up to 600
individuals an hour.
 
 The
approval process can be expensive and may take extended period of time. There
can be no assurance that this system will receive approval from the FDA or if
approved gain broad acceptance by the medical community or individual
patients.
 
 On
December 15, 2005, Medical International Technologies, Inc announced that it has
received full certification granted under the International Organization for
Standardization, as well as the Canadian Medical Device Conformity Assessment
System, for devices to be licensed by HEALTH CANADA. These certifications allow
MIT to market the Med-Jet Needle-Free Injector for human use in all countries
other than the U.S., MIT is working towards getting FDA approval, more test are
required and are being planned at this point. The Med-Jet injector will be
submitted for FDA approval as soon as we complete the required testing which, if
accepted, will allow MIT to sell the Med-Jet in the United States, making it a
truly worldwide system.
 
 MIT's
Needle-Free Injection System, designed specifically to allow fast, accurate and
safe injections, is rapidly moving toward establishing itself as a valuable
instrument in the fight against disease in both humans and animals. Spurred on
by growing fears of a world wide pandemic that could match or even exceed the
deadly flu pandemic of 1918, which killed millions of people, the MIT team is
focusing its efforts to make its Needle-Free Injection System available to the
world.
 
 Now that
MIT is able to sell its Med-Jet in all countries, other than the U.S., it is
working to complete the FDA filings. The first of these will be for use of the
Med-Jet for injecting anesthesia in a variety of situations. The second, and
most significant in light of the news coming out of Mexico and USA and other
countries around the world concerning the spread of Influenza A (H1N1) to
humans, will be the Med-Jet-H-III, for mass vaccination in case of a pandemic,
such as Avian Influenza, Polio, Tuberculosis, Malaria or HIV.
 
 MIT is
also pursuing increasing interest in its Agro-Jet needle-free injector. Having
the same benefits as Med-Jet, Agro-Jet will become a valuable instrument in the
fight against many diseases such as Swine Flue and Avian Flu via its ability to
mass inoculate animals at over 1000 injections per hour.
 
  -13-
  Medical
International Technology, Inc.
 
 
  Forward-Looking
Statements
 
 Certain
statements concerning the Company's plans and intentions included herein may
constitute forward-looking statements for purposes of the Securities Litigation
Reform Act of 1995 for which the Company claims a safe harbor under that Act.
There are a number of factors that may affect the future results of the Company,
including, but not limited to, (a) the ability of the company to obtain
additional funding for operations, (b) the continued availability of management
to develop the business plan and (c) successful development and market
acceptance of the company’s products. This periodic report may contain both
historical facts and forward-looking statements. Any forward-looking statements
involve risks and uncertainties, including, but not limited to, those mentioned
above. Moreover, future revenue and margin trends cannot be reliably
predicted.
 
 Item
3.   Quantitative and Qualitative Disclosures About Market
Risk
 
 Not
required for Smaller Reporting Companies.
 
 Item
4.   Controls and Procedures
 
 Evaluation
of our Disclosure Controls
 As of the
end of the period covered by this Quarterly Report on Form 10-Q, our principal
executive officer and principal financial officer have evaluated the
effectiveness of our “disclosure controls and procedures” (“Disclosure
Controls”). Disclosure Controls, as defined in Rule 13a-15(e) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), are procedures that are
designed with the objective of ensuring that information required to be
disclosed in our reports filed under the Exchange Act, such as this Quarterly
Report, is recorded, processed, summarized and reported within the time periods
specified in the Securities and Exchange Commission’s rules and forms.
Disclosure Controls are also designed with the objective of ensuring that such
information is accumulated and communicated to our management, including the CEO
and CFO, as appropriate to allow timely decisions regarding required disclosure.
Our management, including the CEO and CFO, does not expect that our Disclosure
Controls will prevent all error and all fraud. A control system, no matter how
well conceived and operated, can provide only reasonable, not absolute,
assurance that the objectives of the control system are met. Further, the design
of a control system must reflect the fact that there are resource constraints,
and the benefits of controls must be considered relative to their costs. Because
of the inherent limitations in all control systems, no evaluation of controls
can provide absolute assurance that all control issues and instances of fraud,
if any, within the company have been detected. These inherent limitations
include the realities that judgments in decision-making can be faulty, and that
breakdowns can occur because of simple error or mistake. The design of any
system of controls also is based in part upon certain assumptions about the
likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future
conditions.
 
 Based
upon their controls evaluation, our CEO and CFO have concluded that our
Disclosure Controls are effective at a reasonable assurance level.
  Changes
in internal control over financial reporting
 There
have been no changes in our internal controls over financial reporting during
our third fiscal quarter that have materially affected, or are reasonably likely
to materially affect, our internal control over financial
reporting.
    -14-
 
  
 PART
II OTHER INFORMATION
 
 
 Item
1.   Legal Proceedings
  From time
to time, the Company is named in legal actions in the normal course of business.
In the opinion of management, the outcome of these matters, if any, will not
have a material impact on the financial condition or results of operations of
the Company.
  Item
1A. Risk Factors
 
 Not
required for Smaller Reporting Companies.
 
 Item
2.   Unregistered Sales of Equity Securities and Use of
Proceeds
 
 None.
 
 Item
3.   Defaults upon Senior Securities
 
 None
 
 Item
4.   Submission of Matters to a Vote of Security Holders
 
 None
 
 Item
5.   Other information
  None
 
 Item
6.   Exhibits and Reports on Form 8-K
  Reports on Form
8-K
  NONE
 
 Exhibits
  Medical
International Technology includes herewith the following exhibits.
  31.1           Certification
of Principal Executive Officer pursuant to Rule
13a-14(a)/15(d)-14(a)).
  31.2           Certification
of Principal Accounting Officer pursuant to (Rule
13a-14(a)/15(d)-14(a)).
 
 32.1           Certification
of Principal Executive Officer pursuant to (18U.S.C. 1350)
 
 32.2           Certification
of Principal Accounting Officer pursuant to (18U.S.C. 1350)
   -15-
  
 SIGNATURES
 
 In
accordance with the requirements of the Exchange Act, the registrant caused this
report to be signed on its behalf by the undersigned, thereunto duly
authorized.
 
 Medical International
Technology, Inc.
 Registrant
 
 Date: May
16, 2009
 By:\s\ Karim Menassa,
President
 Karim
Menassa, President and Principal Executive Officer
 
 Date: May
16,
2009
 By:\s\ Michel Bayouk,
Secretary
 Michel
Bayouk, Secretary and Principal Accounting Officer
 
    
 -16-